Results 51 to 60 of about 16,904 (296)
PLoS ONE, 2020 Background Early recognition and diagnosis of allergic bronchopulmonary aspergillosis (ABPA) is critical to improve patient symptoms, and antifungal therapy may prevent or delay progression of bronchiectasis and development of chronic pulmonary ...
E. S. Hunter +3 more
semanticscholar +1 more source
Management of allergic bronchopulmonary aspergillosis: a review and update
Therapeutic Advances in Respiratory Disease, 2012 Since the first description of allergic bronchopulmonary aspergillosis (ABPA) in the 1950s there have been numerous studies that have shed light on the characteristics and immunopathogenesis of this disease.
Mahboobeh Mahdavinia, Leslie C. Grammer
doaj +1 more source
European Journal of Immunology, 2020 Repeated inhalation of airborne conidia derived from the fungus Aspergillus fumigatus (Af) can lead to a severe eosinophil‐dominated inflammatory condition of the lung termed allergic bronchopulmonary aspergillosis (ABPA).
Axel Dietschmann +3 more
semanticscholar +1 more source
Cureus, 2020 Allergic bronchopulmonary aspergillosis (ABPA) is an eosinophilic pulmonary disorder caused by a hypersensitivity reaction to Aspergillus fumigatus that manifests with uncontrolled asthma, peripheral blood eosinophilia, and radiological findings, such as
Amirseena Tolebeyan +3 more
semanticscholar +1 more source
Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa +2 more
wiley +1 more source
Specific Antibodies to Recombinant Allergens of \u3cem\u3eAspergillus fumigatus\u3c/em\u3e in Cystic Fibrosis Patients with ABPA [PDF]
, 2006 Background Aspergillus fumigatus, a widely distributed fungus, has been implicated in causing life threatening infections as well as severe asthma and allergic diseases in man.
Bansal, Naveen K. +3 more
core +1 more source
Internal medicine, 2020 We herein report a 56-year-old woman who developed allergic bronchopulmonary aspergillosis (ABPA) possibly due to fungal exposure after disastrous heavy rainfall in Western Japan in 2018.
H. Matsuura +11 more
semanticscholar +1 more source
Mycoses, Volume 69, Issue 2, February 2026.ABSTRACT Introduction Relapses occur in up to 40% of patients after prolonged courses of antifungal treatment for chronic pulmonary aspergillosis (CPA). The factors predisposing to relapse remain poorly defined. Methods We conducted a retrospective study of adults treated for ≥ 6 months with oral azoles for CPA.
Annabel Choyce +6 more
wiley +1 more source
Clinical Case Reports, 2021 As diagnostic algorithms for cystic fibrosis (CF) continue to evolve, education of general practitioners is essential to prevent delayed diagnosis of CF and allow prompt referral to CF centers.
Patricia Choi +2 more
doaj +1 more source
Mepolizumab use in cystic fibrosis‐associated allergic bronchopulmonary aspergillosis
Respirology Case Reports, 2020 Allergic bronchopulmonary aspergillosis (ABPA) is common in cystic fibrosis (CF). Treatment is challenging and the relapse rate is high. Standard therapy is oral steroids and antifungals.
M. Boyle +5 more
semanticscholar +1 more source